Navigation Links
Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
Date:11/6/2013

SAN DIEGO, Nov. 6, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that it has entered into a commercial supply agreement with Sanofi to act as Orexigen's contract manufacturer for Contrave® (32 mg naltrexone sustained release (SR) / 360 mg bupropion SR) for territories outside North America.  Sanofi will manufacture Contrave tablets at one of several facilities in France.

"We are pleased to engage a manufacturer with Sanofi's scale and expertise," said Michael Narachi, CEO of Orexigen. "This agreement expands and diversifies our existing commercial supply network and will help ensure we will be ready to supply Contrave globally if approved."

About Contrave
Orexigen is evaluating Contrave for the management of obesity, including weight loss and maintenance of weight loss, in conjunction with lifestyle modification, and is currently conducting the Light Study, a cardiovascular outcomes trial. The primary objective of the double‐blind, randomized, placebo‐controlled clinical trial, which Orexigen is conducting under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis of the Light Study is anticipated by early December, enabling the potential resubmission of the Contrave New Drug Application (NDA) to the FDA by year end.

In October Orexigen submitted a Marketing Authorization Application (MAA) for Contrave to the European Medicines Agency (EMA).

Orexigen has licensed North American Contrave commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights in Europe and
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
2. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
3. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
4. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
5. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
6. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
7. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
8. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
9. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
10. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
11. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... December 25, 2014 AngelWeddingDress.com tries its ... the online realm. Today, the business has introduced its ... site-wide prom dress promotion. , The new prom outfits ... and every dress lover. They are specially designed for ... prom dresses should visit its website before Jan. ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part ... mobile applications on the iOS, Android, and Windows markets. Andrew ... the app review and shared with viewers how this is ... old saying goes, “A picture says a thousand words.” It’s ... a single image, because each picture holds a unique and ...
(Date:12/25/2014)... Newton, North Carolina (PRWEB) December 25, 2014 ... a North Carolina Retirement Community, recently showed their ... and girls of the Catawba County Parenting Network- ... meal, the 10 children gathered around the largest ... community to open presents purchased by residents of ...
(Date:12/25/2014)... AZ (PRWEB) December 25, 2014 Parker ... to outstanding customer service and affordable quality regarding heating, ... area announces recognition in 2014 by the “Queen of ... Sons has earned an impressive reputation over the years ... on a wide range of contractor services for both ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3
... good for heart health, at least among men, a ... researcher Robert Gramling, M.D., D.Sc., found that men who ... actually experienced a three times lower incidence of death ... not support the same conclusion among women. One possible ...
... Australian first, scientists at Sydney,s Centenary Institute have mapped ... has the potential to turn the way we discover ... time for new treatments. , "These membrane proteins are ... an increased,understanding of them is vital for future drug ...
... Theoretical Bioinformatics at the German Cancer Research Center (Deutsches ... how cells decide whether or not to migrate. Using ... molecular targets within a cell that have to be ... direction. This method may help to develop new treatments ...
... YORK and PARSIPPANY, N.J., July 14 Healthfirst ... a free online service,for electronic claims submissions. This ... medical providers to do business with the health ... faster exchange of,information, higher acceptance rates and quicker ...
... announced the appointment of Gregory Ciottone,MD to the position of Chief ... ... Company., LONGMONT, Colo., July 14 ... Ciottone, MD,to the position of Chief Medical Officer. Dr. Ciottone will ...
... Combat Lifesaver ... ... the summer of 2005, the,U.S. Army approached Recon Mountaineer(R) LLC ... the Combat Lifesaver program, and,at gaining their approval, the TC3(R) ...
Cached Medicine News:Health News:Positive thinking is prescription for the heart 2Health News:Discovery first step to new therapies 2Health News:Cellular decision on the computer 2Health News:Healthfirst and MD On-Line Partner to Streamline Claims Processing 2Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 2Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 3Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 4Health News:American Hospital Management Company Appoints Gregory Ciottone, MD as Chief Medical Officer 5Health News:Creator of Recon Moutaineer's Tactical Combat Casualty Care Bag Praises Combat Lifesavers 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: